Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
J&J Buys Aragon For Cancer Drug
by Michael McCoy
June 24, 2013
| A version of this story appeared in
Volume 91, Issue 25
Johnson & Johnson has agreed to acquire Aragon Pharmaceuticals, a San Diego-based small-molecule biotech firm, for $650 million plus up to $350 million in milestone payments. J&J is buying the four-year-old company mainly for ARN-509, an androgen receptor antagonist that is in Phase II clinical trials to treat patients with castration-resistant prostate cancer. Before the deal closes, Aragon will spin off a new company, Seragon Pharmaceuticals, that will focus on Aragon’s selective estrogen receptor degrader program, including ARN-810, which is in a Phase I trial for metastatic breast cancer.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter